Suven Life Sciences Faces Surging Losses Amid Rising Expenses

Suven Life Sciences Ltd faces financial challenges as its consolidated net loss widened significantly to Rs 43.95 crore for the fourth quarter ending March 31, 2025. The downturn is attributed to a sharp decline in revenues and escalating expenses.

The company's prior performance had recorded a smaller consolidated net loss of Rs 26.54 crore during the same quarter the previous fiscal year, reflecting a concerning trend. Revenue for the quarter under review plummeted to Rs 1.47 crore from Rs 2.39 crore, signifying a notable drop.

Total expenses spiked to Rs 46.63 crore, as opposed to Rs 34.21 crore a year ago. For the fiscal year 2024-25, Suven Life Sciences also noted a widened net loss of Rs 160.75 crore from the prior year's Rs 105.08 crore, with revenues falling to Rs 6.66 crore from Rs 11.69 crore.

(With inputs from agencies.)